Inactive Instrument

Oncorus, Inc.

Equities

ONCR

US68236R1032

Biotechnology & Medical Research

Oncorus, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 04, 2021 at 07:10 am EDT

Oncorus, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 15.549 million compared to USD 8.748 million a year ago. Net loss was USD 15.528 million compared to USD 9.374 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 12.09 a year ago. For the half year, operating loss was USD 28.218 million compared to USD 16.692 million a year ago. Net loss was USD 28.191 million compared to USD 17.201 million a year ago. Basic loss per share from continuing operations was USD 1.13 compared to USD 22.67 a year ago.

Latest news about Oncorus, Inc.

North American Morning Briefing : Fed Seen Holding Rates, Powell Comments Key	23-09-20	DJ
North American Morning Briefing : Inflation -2-	23-09-06	DJ
North American Morning Briefing : Stock Futures -2-	23-08-30	DJ
North American Morning Briefing : Nvidia Results -2-	23-08-23	DJ
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
North American Morning Briefing : Traders Absorb -2-	23-08-09	DJ
Oncorus, Inc. Announces Executive Changes	23-08-03	CI
Oncorus, Inc. Announces Changes to Its Board	23-08-03	CI
Oncorus, Inc. Announces Executive Changes	23-08-03	CI
Oncorus, Inc. Announces Board Changes	23-07-28	CI
Oncorus, Inc. Announces Resignation of Douglas M. Fambrough III from its Board of Directors as Well as Compensation Committee, Effective July 20, 2023	23-07-19	CI
Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	23-07-19	CI
Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index	23-06-23	CI
Oncorus, Inc.(OTCPK:ONCR) dropped from NASDAQ Composite Index	23-06-20	CI
Oncorus Announces Management Changes	23-06-07	CI
Oncorus Appoints Brian Shea as Interim Chief Executive Officer	23-06-07	CI
Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-06-02	MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus	23-06-02	DJ
Oncorus to Lay Off Almost Entire Workforce -- Shares Slump After-Hours	23-06-01	MT
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	23-06-01	DJ
Oncorus, Inc. Announces Workforce Reduction Plan	23-06-01	CI
Theodore Ashburn, Chief Executive Officer Departs from the Oncorus, Inc, Effective to Be No Later Than June 30, 2023	23-06-01	CI
Oncorus, Inc. Announces Management Changes, Effective to Be No Later Than June 30, 2023	23-06-01	CI
Oncorus, Inc. Contemplates Bankruptcy	23-06-01	CI
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI

Chart Oncorus, Inc.

Duration

Period

More charts

Company Profile

Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs